Turner Syndrome Global Market Report 2025

The turner syndrome market size has grown strongly in recent years. It will grow from $2.36 billion in 2024 to $2.55 billion in 2025 at a compound annual growth rate (CAGR) of 8%. The growth in the historic period can be attributed to increasing awareness of women's health, rising healthcare expenditure, the expansion of the healthcare sector, greater awareness and early diagnosis of Turner syndrome, and public awareness initiatives.

The turner syndrome market size is expected to see strong growth in the next few years. It will grow to $3.42 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to the rising cases of structural abnormalities of the X chromosome, the widespread adoption of estrogen replacement therapy, the increasing use of chromosomal microarray analysis (CMA) for disease diagnosis, a growing female population, and expanding research and development activities. Key trends during this period include the adoption of new technologies, product launches, advancements in growth hormone therapy, rising demand for hormonal treatments, and the development of novel therapies.

The increasing female population is expected to drive the growth of the Turner syndrome treatment market. As the global female population expands due to factors such as higher life expectancy, improved healthcare, and demographic shifts, the demand for specialized treatments for Turner syndrome rises. Turner syndrome treatment supports affected individuals through growth hormone therapy to enhance stature, estrogen replacement for puberty induction and bone health maintenance, and multidisciplinary care to manage associated conditions. According to the U.S. Census Bureau, as of July 2022, the United States had approximately 168 million females, with 1.9 million more women aged 85 and older. Additionally, CEIC Data reported in December 2022 that the number of females aged 15-64 had risen from 2,940,645 in 2021 to 2,951,856 in 2022. This demographic trend is contributing to the increased demand for Turner syndrome treatments.

Advancements in pediatric growth hormone therapies are also driving market growth. Major pharmaceutical companies are conducting clinical trials to develop innovative products aimed at improving height outcomes and overall development in children with Turner syndrome and growth-related disorders. Pediatric growth hormone medications, particularly synthetic or recombinant hormones, play a crucial role in stimulating growth in children with deficiencies. For instance, in December 2024, Ascendis Pharma A/S announced positive Phase 2 trial results for TransCon hGH (lonapegsomatropin) in children aged 1-10 years with Turner syndrome. The trial demonstrated that TransCon hGH provided growth improvements comparable to daily somatropin, with a similar safety profile. These promising results could expand the market for growth hormone treatments in Turner syndrome patients.

In December 2024, Double Point Ventures (DPV) acquired Lumos Pharma for $38 million to enhance its portfolio in biopharmaceutical therapeutics for rare diseases. Lumos Pharma’s lead candidate, LUM-201, an oral growth hormone secretagogue currently in Phase 2 clinical trials for pediatric growth hormone deficiency, has the potential to impact Turner syndrome treatment. By integrating Lumos Pharma’s expertise, DPV aims to drive further innovation in growth hormone therapy and broaden treatment options for patients with Turner syndrome.

Major players in the turner syndrome market are Pfizer Inc., Sanofi SA, AstraZeneca Plc, Abbott Laboratories, Novartis AG, LG Chem Ltd., Eli Lilly and Company, Novo Nordisk, Merck KGaA, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Genentech Inc., Ipsen Pharma, Ferring Pharmaceutical, BioMarin Pharmaceutical Inc., United Imaging Healthcare Co. Ltd., Daewoong Pharmaceutical Co. Ltd., OPKO Health Inc., Hanmi Pharmaceutical Co. Ltd., Dong-A ST Co. Ltd., GeneScience Pharmaceuticals Co. Ltd., Ascendis Pharma, AnkeBio Co. Ltd., Biopartners Inc., Kexing Biopharm Co. Ltd.

North America was the largest region in the turner syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in turner syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the turner syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Turner syndrome is a genetic condition affecting females, caused by the partial or complete absence of one X chromosome. It can lead to various developmental and medical challenges, including short stature, delayed puberty, infertility, heart defects, and certain learning difficulties. Diagnosis is typically performed through karyotype testing, and management involves specialized medical care to address associated health concerns.

The main types of Turner syndrome include classical Turner syndrome and mosaic Turner syndrome. Classical Turner syndrome is the most common form, characterized by the complete absence of one X chromosome in females. Treatment options include growth hormone therapy, estrogen and progesterone replacement therapy, and other supportive therapies. Several drugs are used for this condition, including Norditropin, Oxandrolone, Humatrope, Somatropin, Oxandrin, Genotropin, Nutropin, and Zomacton. These treatments are utilized by various end users, such as hospitals, home care settings, specialty clinics, and surgical centers.

The turner syndrome market research report is one of a series of new reports that provides turner syndrome market statistics, including turner syndrome industry global market size, regional shares, competitors with a turner syndrome market share, detailed turner syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the turner syndrome industry. This turner syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The turner syndrome market consists of revenues earned by entities by providing services such as genetic counseling, diagnostic testing services, fertility and reproductive health support. The market value includes the value of related goods sold by the service provider or included within the service offering. The turner syndrome market also includes sales of genetic testing kits, cardiac monitoring devices and bone density supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.